| |
Total
|
CTRLs
|
AD
|
|---|
|
Series
|
N
|
N
|
%F
|
%ε4+
|
Age
|
N
|
%F
|
%ε4+
|
Age
|
|---|
|
A) Mayo postmortem
|
365
|
173
|
35.3
|
26.0
|
71.7
|
192
|
51.6
|
63.0
|
73.5
|
|
B) All
|
10,842
|
6,175
|
54.4
|
23.4
|
77.6
|
4,667
|
61.1
|
62.3
|
76.6
|
|
Mayo Clinic
|
6,307
|
4,250
|
54.0
|
23.3
|
78.7
|
2,057
|
60.7
|
59.9
|
79.3
|
|
NCRAD
|
910
|
209
|
61.7
|
16.3
|
78.3
|
701
|
64.8
|
78.5
|
75.2
|
|
Norway
|
927
|
569
|
59.6
|
24.6
|
74.9
|
358
|
69.8
|
63.1
|
79.4
|
|
ARUK
|
2,698
|
1,147
|
51.6
|
24.2
|
74.7
|
1,551
|
58.0
|
58.0
|
73.0
|
- Demographic details are shown for (A) Samples taken from the cerebellum of autopsy-confirmed AD patients and controls and used for genotype versus mRNA analyses and (B) Samples from the Mayo Clinic, Indiana, Norway and Alzheimer’s Research UK (ARUK) Consortium case-control series used for the case-control association study. N; number of samples, %F; percent females, %ε4; percent APOE ε4 carriers, Age; years.
